|Covalon Technologies Ltd -- Canada Stock|| |
CAD 4.27 0.33 7.17%
Co-Founder and Chief Science Officer
Dr. Valerio DiTizio serves as a Chief Scientific Officer of Covalon Technologies Ltd., since December 21, 2004. Dr. DiTizio is a coinventor of Covalon technologies and a cofounder of the company. He has degrees in science from the University of Toronto as a Biochemistry Specialist. Dr. DiTizio completed his Master degree in liposome drug delivery. His graduate research involved the application of polymer chemistry and drug delivery in pursuit of novel materials and processes that currently comprise the core of Covalons intellectual property. Dr. DiTizio holds several US and European patents.
Age: 48 Founder Since 2004
The company has return on total asset (ROA)
of 11.16 %
which means that it generated profit of $11.16 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 24.61 %
meaning that it generated $24.61 on every $100 dollars invested by stockholders.
Covalon Technologies Ltd. researches, develops, manufactures, markets, and licenses medical technologies and products worldwide. The company offers its technologies, products, and services to various health care providers, such as hospitals, wound care centers, burn centers, extendedalternate care facilities, acute care facilities, home health care agencies, and physicians offices. Covalon Technologies operates under Biotechnology classification in Canada and traded on TSX Venture Exchange exchange.Covalon Technologies Ltd (COV) is traded on TSX Venture Exchange in Canada. It is located in 1660 Tech Avenue and employs 8 people.